Shots:
- The US FDA has granted Fast Track designation to Lu AH69593 for the treatment of patients with narcolepsy
- Lu AH69593 is a small-molecule orexin 2 receptor agonist being developed by Lundbeck for narcolepsy to regulate arousal, wakefulness, & sleep-wake stability
- Lu AH69593 is being evaluated in a P-Ib clinical program, with Lundbeck continuing to assess its safety, tolerability, PK & PD profile
Ref: PRnewswire | Image: Lundbeck | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
